welcome to callisto pharmaceuticals
Callisto Pharmaceuticals, Inc., is a publicly
traded biotechnology company on the OTC Bulletin Board (CLSP.OB).
The company has novel candidates in the pipeline for therapeutic
intervention of multiple myeloma, colon cancer and for gastrointestinal
inflammation. The company is also developing, in collaboration
with the Rockefeller University, innovative therapeutic products
for bioterrorism defense.
Callisto Pharmaceuticals submitted an IND
in September 2003 for clinical evaluation of Atiprimod for
multiple myeloma. This trial is anticipated to begin in December
2003. Atiprimod is a novel anti-angiogenic and cytotoxic agent
that also has considerable potential in treatment of other